US Early Feasibility Studies (EFS)

Slides:

Advertisements

Similar presentations

Post Research Benefits Mandika Wijeyaratne MS, MD, FRCS Dept. of Surgery, Colombo.

Advertisements

Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development IND Regulatory.

John Naim, PhD Director Clinical Trials Research Unit

Special Topics in IND Regulation

Overview of Good Clinical Practices (GCPs)

International Human Subject Research Legal and Ethical Considerations for Investigators Theresa J. Colecchia, Esq. Associate General Counsel May 8, 2006.

Investigating recent developments in clinical trials in Belgium: analysis of the data available at the Federal Agency for Medicines and Health Products.

Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.

Fourth Annual Medical Research Summit Concurrent Session 4.05 – Managing CROs and SMOs from a Compliance Perspective Michael SwiatochaAprill 23, 2004.

Investigational New Drug Application (IND)

Planned Emergency Research Exception from Informed Consent Requirements September 2007.

INDs : Does My Study Need One? Edith Paal UAMS Office of Research Compliance August 22, 2003.

University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.

Compliance with FDA Regulations: Collecting, Transmitting and Managing Clinical Information Dan C Pettus Senior Vice President iMetrikus, Inc.

The QA/QI Process Human Research Subjects Protection Human Investigation Committee Tracy Rightmer, JD, CIP Compliance Manager.

Yale Center for Clinical Investigation: Academic Home to the CTSA Secretary’s Advisory Committee on Human Research Protections (SACHRP) Presentation Tesheia.

© 2009 Cengage Learning. All Rights Reserved. Clinical Research.

Questions: AAHRPP Evaluation Instrument for Use with Final Revised Accreditation Standards Presented by: C. Karen Jeans, MSN, CCRN, CIP COACH Program Analyst,

Building Clinical Infrastructure and Expert Support Michael Steinberg, MD, FACR ULAAC Disparity Project Centinela/Freeman Health System.

UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.

Single Patient Use of Investigational Anticancer Agents: An Industry Perspective Gerard T. Kennealey, MD Vice President, Clinical Research, Oncology AstraZeneca.

Welcome New IRB Members! Today we will discuss: Your Role in the IRB: What to Know The IRB Review Process Resources Human Research Protections.

Yadvindera (Bobby) Bains MD Director of Radiation Oncology, Laredo Medical Center Adjunct Associate Professor, Dept of Radiation Oncology, University of.

Module C FDA Regulations Regulatory Documents Patricia E. Koziol 1Module C Final Version 10-apr-2010.

Welcome New IRB Member! This brief presentation covers: Your Role in the IRB: What to Know The IRB Review Process Resources Human Research Protections.

The TJU Human Research Protection Program (HRPP): Part I – Which Entities/Offices are Involved ? J. Bruce Smith, MD, CIP.

21 CFR Toby A. Silverman, M.D. Branch Chief, Clinical Review Branch Division of Hematology, Office of Blood December 14, 2006.

EXCEPTION FROM INFORMED CONSENT IN CPR DEVICE TRIALS: PROTECTION OF PATIENTS’ RIGHTS Circulatory System Devices Panel Meeting September 21, 2004 Elisa.

Responsibilities of Sponsor, Investigator and Monitor

Collaborative Institutional Training Initiative (CITI) citiprogram.org Georgia Institute of Technology.

Cancer Clinical Trials Office Clinical Trials & Research Training Oct2014.

Rachel Neubrander, PhD Division of Cardiovascular Devices

Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP

Research Compliance and Institutional Review Boards

Contract Research organizations

Responsibilities of Sponsor, Investigator and Monitor

Patricia M. Alt, Ph.D. Dept. of Health Science Towson University

OUS Data: What does the CE Mark Really Mean?

Clinicaltrials.gov Update

The HIPAA Privacy Rule: Implications for Medical Research

Jeff Shuren, MD, JD Center for Devices and Radiological Health U. S

The Information Professional’s Role in Product Safety

FDA’s IDE Decisions and Communications

How to Put Together an IDE Application

Balancing Regulation and Innovation: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

How to Apply for and Receive Industry Funding for Investigator Sponsored Research Chuck Simonton MD, FACC, FSCAI Chief Medical Officer Abbott Vascular.

Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.

The FDA Early Feasibility Study Pilot and the Innovation Pathway

IRB – Human subjects research incoming staff orientation 2017

The Current PMA Requirements

FDA Guidance on Early Feasibility Studies, Including First-in-Human

First-in-Man, First In The USA: What’s The Difference?

Introduction of New Technology: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP

Benefits of US EFS: A Clinical Perspective

Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

Early Feasibility in the USA –An Academic View

Lessons Learned Through HBD: The Regulator’s View - US FDA

Bozeman Health Clinical Research

FDA-CDRH in the Next Decade A Vision for Change

Infrastructural Support – Enabling CTS

Elements of an Organized Regulatory Binder

IRB – Human subjects research incoming staff orientation 2018

Streamlining IRB Procedures for Expanded Access

FDA Medical Device Approval Pathways

Timothy B. Cleary, Esq. Meredith Manning, Esq.

Opening an IND: Investigator Perspective

Research, Experimentation, & Clinical Trials

Regulatory Perspective of the Use of EHRs in RCTs

Presentation transcript:

US Early Feasibility Studies (EFS) A Medical Device Company Perspective Why I Don't Conduct EFS in the US Keith Dawkins MD FRCP FACC FSCAI Global Chief Medical Officer Executive Vice President Boston Scientific Corporation

Conflicts of Interest Boston Scientific Corporation Employee Stockholder

Disclaimer US Early Feasibility Studies (EFS) A Medical Device Company Perspective Why I Don't Conduct EFS in the US This title was chosen by Ron Waksman MD, and does not reflect the views of Boston Scientific Corporation…!

‘FDA recognizes the value of encouraging medical device innovation to address clinical needs and improve patient care, particularly when alternative treatments or assessments are unavailable, ineffective, or associated with substantial risks to patient safety. This guidance has been developed to facilitate the early clinical evaluation of medical devices in the United States under the IDE regulations, using risk mitigation strategies that appropriately protect human subjects in early feasibility studies…’

Impediments to Clinical Research Regulations Sponsor-imposed impediments to Clinical Research Academic Institutions: impediments to Clinical Research Health Systems & clinical practice sites: impediments to Clinical Research Kramer JM: Clin Pharmacol Ther 2012;91:535-541

Impediments to Clinical Research Regulations US Federal Electronic records (21 CFR 11) Human subject protections (21 CFR 50) Financial disclosure by clinical investigators (21 CFR 54) Institutional review boards (21 CFR 56) Investigational new drugs and biologics (21 CFR 312) IND safety reporting (21 CFR 312.32) Sponsor obligations 21 CFR 312.50; 812.40 Investigator obligations 21 CFR 312.60 Investigational devices (21 CFR 812) Privacy laws (45 CFR 164) US State European Clinical Trials Directive Other national regulatory authorities Kramer JM: Clin Pharmacol Ther 2012;91:535-541

Clinical Research Challenges US Clinical Trial Enrollment Delays Worsen Percent (%) Source: CenterWatch Surveys of Investigation Sites

Current Clinical Research Environment A Growing Proportion of Novice Investigators Note: Experienced Investigators conducted at least one study in the prior year Source: CenterWatch Analysis of FDA BMIS Database (2011)

Current Clinical Research Environment The Increasing Proportion of Low-Volume Investigators File 1 1572 Annually File 2-4 1572s Annually File ≥5 1572s Annually 0.7% Source: CenterWatch (2011)

Metrics for Successful Clinical Research Clinical Expertise Experience with Clinical Trials Necessary Clinical Trial Infrastructure Available Target Patient Population Compliance High Data Quality Data acceptable for Regulatory Approval Cost Timeliness to FPI & Trial Completion

Conclusions Effective Clinical Trial execution is judged by the most rapid negotiation of the numerous barriers inherent in navigating the country-specific regulatory pathway Ultimately, speed to market defines commercial success Many factors determine geographic selection for site participation and patient enrolment If the US can be shown to be competitive (and a ‘fast’ FDA pathway for First Human Use or Feasibility Trials is only one element of the clinical trial paradigm), then Boston Scientific would welcome the opportunity of early domestic device evaluation